Pharma Benefits Executive Michael Darkoch Joins CNS Response

ALISO VIEJO, CA–(Marketwire – July 12, 2010) –  CNS Response (OTCBB: CNSO) announces the appointment of Michael E. Darkoch as Executive Vice President and Chief Marketing Officer. In this role, Darkoch will assume all responsibility for the launch and commercialization of the Company’s flagship product, Referenced-EEG, including all marketing, business development and patient advocacy activities.

“Mike is a known quantity,” said CNS Response CEO George Carpenter. “In the world of pharmaceutical benefits, he understands what drives consumers, what payers pay for, and how to scale services around them. His industry expertise and payer relationships will be incredibly valuable as we introduce Referenced-EEG to a broader market. I’ve worked with Mike in three companies and his experience, skills and performance record will be crucial to our future success.”

Darkoch joins CNS Response with extensive executive experience at healthcare companies including Baxter International, CORE, Inc, and pharmaceutical benefits management firm Caremark Rx, where he grew sales from $100 million to $2.1 billion within five years, while achieving an industry record of 98 percent client retention for a two-year period. 

Prior to joining CNS Response, Darkoch held senior management positions with MedImpact Health Systems, a prescription benefit management firm in San Diego, where he successfully managed product development and increased new sales revenues 15 percent, market segment revenues by 40 percent and specialty products’ revenues by 35 percent. 

Darkoch commented, “One of the greatest challenges in the pharmaceutical arena is to understand how medications will impact patients differently, and mental disorders represent one of the largest opportunities where numerous medications have individualized outcomes.

“I believe Referenced-EEG may offer an important answer, helping physicians improve clinical outcomes for patients, and economic outcomes for us all. My goal is to establish the CNS Response brand and reputation quickly in this emerging area of personalized medicine.”

Darkoch holds a Bachelor of Science of Industrial Engineering from Lehigh University and Master of Science in Business from Southern Methodist University. He started his engineering and management career with Texas Instruments and Mobil Chemical Company, before moving into the healthcare and pharmaceutical sectors.

About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

Referenced-EEG was developed by physicians to provide objective, personalized, statistical data on patient neurophysiology. In clinical trials, physicians using rEEG data have consistently achieved superior clinical results compared to physicians using trial and error pharmacotherapy.

The Company announced publication last week of results from its most recent clinical trial in The Journal of Psychiatric Research, in which physicians using Referenced-EEG (rEEG^®₎ had success rates reaching 65 percent for patients with treatment-resistant depression.

To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Click here to see all recent news from this company